阿糖胞苷体内代谢酶活性与临床耐药的关系  

Correlation between Ara-C-metabolizing enzymes and resistant leukemia

作　　者：万海霞[1] 赵劲秋[1] 欧阳仁荣[1] 

机构地区：[1]上海第二医科大学仁济医院白血病研究室,上海,200001

出　　处：《上海第二医科大学学报》2004年第3期218-220,共3页Acta Universitatis Medicinalis Secondae Shanghai

摘　　要：阿糖胞苷(Ara-C)是治疗急性髓细胞白血病(AML)的首选药物之一,以Ara-C为主的诱导方案可使60％～80％的病人获得完全缓解(CR),但仍有许多病人不能缓解或缓解后复发,究其原因,耐药问题占很大比重。AML病人对Ara-C的耐药机制有多种,其中Ara-C代谢酶与临床耐药关系较大,该文试从代谢酶角度对这一问题进行探讨。Cytosine arabinoside ( Ara-c) is the first choice and a standard drug in the treatment of aeute myeloid leukemia( AML). Most treatment regimens usually including Ara-C may induce complete remission ( CR) in 60%-80% patients. However, some patients still can not reach CR or relapse finally, probably due to clinical resistance, either present at diagnosis or evolving with relapse. Several mechanisms of cellular drug resistance have been described in patients with AML, and Ara-C metabolizing enzymes may be the most important factor. Correlation between Ara-C-metabolizing enzymes and resistant leukemia will be described in this article.

关 键 词：阿糖胞苷 代谢酶 耐药 急性髓细胞白血病 体内代谢 P糖蛋白 

分 类 号：R96[医药卫生—药理学]